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Purpose: The aim of this study was to compare the prognostic value of interleukin 6 (IL-6), galectin 3, growth dif-
ferentiation factor 15 (GDF-15), and soluble ST2 (sST2) in an unselected cohort of critically ill patients.
Methods: During a study period of 1 year, we recruited 530 consecutive patients admitted to a medical intensive
care unit of a tertiary care hospital. We examined a combination of inﬂammatory, renal, and cardiac biomarkers
for the prediction of 90-day all-cause mortality.
Results: During follow-up, 118 patients died (22%). In univariate analyses, increased IL-6, galectin 3, GDF-15, and
sST2 plasma concentrations at baseline were strong prognostic markers. However, in the multivariate models,
only IL-6 and sST2 remained independent biomarkers adding additional prognostic information to the routinely
used Simpliﬁed Acute Physiology Score (SAPS) II. Using a simple multimarker approach, patients with increased
SAPS II, IL-6, and sST2 (ie, SAPS II N35, IL-6 N32.3 pg/mL, and sST2 N103 ng/mL) had the poorest outcome.
Conclusions: In this heterogeneous group of critically ill patients, only SAPS II, IL-6, and sST2 remained indepen-
dent and additive prognosticmarkers for 90-day all-causemortality. A combination of the SAPS IIwith the 2 com-
plementary biomarkers might provide a valuable tool for risk stratiﬁcation of critically ill patients.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
General illness severity scores such as the Simpliﬁed Acute Physiol-
ogy Score (SAPS) are widely used in intensive care units (ICUs) to char-
acterize disease severity and to predict outcome using physiological
data available at admission to the ICU [1,2]. Further tools for risk strati-
ﬁcation of ICUpatientswould beuseful. In this context,we have demon-
strated that the biomarker soluble ST2 (sST2), an interleukin 1 receptor
family member, was a strong and independent predictor of 90-day all-
cause mortality in an unselected cohort of patients admitted to the
ICU, which even added prognostic information to the SAPS II [3]. Fur-
thermore, we have recently shown in an explorative study that galectin
3, a soluble β-galactosidase-binding lectin, and growth differentiation
factor 15 (GDF-15), a transforming growth factor super family member,
were not only increased in heart failure but also in several other noncar-
diac diseases such as inﬂammatory and infectious diseases [4]. Interleu-
kin 6 (IL-6), a well-established proinﬂammatory cytokine, is routinely
used in critically ill patients [5].ry Medicine, Konventhospital
tria. Tel.: +43 732 7677 3620;
plinger).
. This is an open access article underThe aim of this study was to compare the prognostic value of IL-6,
galectin 3, GDF-15, and sST2 in an unselected cohort of critically ill pa-
tients. We tested the hypothesis that these biomarkers determined at
baseline are independent predictors of 90-day all-causemortality in pa-
tients admitted to an ICU. In addition, we assessed the prognostic value
of change of biomarkers over time.
2. Materials and methods
2.1. Study population
To evaluate the capability of IL-6, galectin 3, GDF-15, and sST2 mea-
surements for mortality prediction in ICU patients, we used our data
from the Linz Intensive Care Unit (LICU) study [3], which was designed
todetermine thepredictive value of candidate biomarkers to predict 90-
day all-cause mortality in an unselected cohort of critically ill patients.
The studyprotocolwas approved by the local ethics committee in accor-
dance with the Declaration of Helsinki, and all study participants gave
informed consent. The LICU study objectives, recruitment procedures,
and characteristics have been described in detail previously [3]. In
brief, between February 2009 and February 2010, 530 consecutive pa-
tients admitted to the 8-bed medical ICU of a tertiary care hospital (Stthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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were age 18 years or older, no known pregnancy, and no previous ad-
mission to ICU during the study period.
In all patients, baseline demographics, primary diagnosis (ie, the sin-
glemost applicable reason for ICU admission), and a clinical score of dis-
ease severity were recorded. The primary diagnosis was retrieved from
themedical records and categorized according to Knaus et al [6]. Sever-
ity of diseasewas quantiﬁed by the SAPS II [7]. The SAPS II was routinely
assessed on the day of admission and after 48 hours with an automated
ICU documentation system ICdoc Pro V7.4.3.AT (ASDI, Vienna, Austria).
2.2. Biochemical analyses
Using VACUETTE polyethylene terephthalate glycol blood collection
tubes (Greiner Bio-One, Kremsmuenster, Austria), EDTA and serum
sampleswere collected. For baseline evaluation, bloodwas drawnwith-
in 24 hours after admission to the ICU. Patients with a length of stay
more than 48 hours at the ICU had a second blood draw approximately
2 days after the baseline blood draw as part of the routine morning
blood sampling. C-reactive protein (CRP) plasma concentrations were
measured with the standard laboratory method Tina-quant CRP
(Latex), processed on a Modular platform (Roche Diagnostics, Vienna,
Austria); procalcitonin (PCT) serum concentrations were determined
using the VIDAS B.R.A.H.M.S. PCT assay on a VIDAS instrument
(bioMérieux, Vienna, Austria); IL-6, creatinine (Jaffé method), and
high-sensitivity cardiac troponin T (hs-cTnT) plasma concentrations
were measured with standard assays on a Modular platform (Roche Di-
agnostics); B-type natriuretic peptide (BNP) plasma concentrations
were measured by using the ARCHITECT BNP assay on the ARCHITECT
I2000SR System (Abbott Diagnostics, Vienna, Austria).
Soluble ST2 plasma concentrations were measured fully automated
on a BEP 2000 instrument (Siemens Healthcare Diagnostics, Vienna,
Austria) with the Presage ST2 sandwich immunoassay assay (Critical
Diagnostics, San Diego, CA), as previously reported [3,8].
Wemeasuredgalectin 3plasma concentrationswith a chemiluminescent
microparticle immunoassay on an ARCHITECT I2000SR analyzer (Abbott Di-
agnostics) and GDF-15 plasma concentrations with a precommercial chemi-
luminescent microparticle immunoassay on a Hitachi cobas e411 analyzer
(Roche Diagnostic), as recently reported [4].
C-reactive protein, PCT, IL-6, creatinine, andBNPwere quantiﬁedwithin
2 hours of blood collection in all study participants. EDTA plasma aliquots
were stored at−80°C for further analysis. One of these plasma aliquots
was used for the determination of hs-cTnT and sST2 3months after the re-
cruitment periodwas closed. Plasma concentrations of galectin 3 and GDF-
15weremeasured in 1 batch from another thawed plasma aliquot in 2014.
2.3. Mortality ascertainment
The entire cohort received follow-up for ICU, inhospital, and 90-day
mortality. Mortality data were obtained from the medical records and
the Austrian Death Registry. The Austrian Death Registry includes all
deaths within Austria and the deaths of Austrian citizens in foreign
countries if reported to Austrian ofﬁcials. The primary outcome variable
of the present follow-up investigation was all-cause mortality, deﬁned
as all-cause death occurring during the observation period. The second-
ary outcome variable of this study was cardiovascular mortality, which
was deﬁned according to the International Statistical Classiﬁcation of Dis-
eases, 10th Revision, with codes I00-I79. All study participants received
follow-up, and the observation period for each of them was appointed
to 90 days or until death if occurred earlier.
2.4. Statistical analysis
Data were statistically analyzed with SPSS 13.0 software (SPSS, Inc,
Chicago, IL) and MedCalc 13.1.2.0 package (MedCalc Software,
Mariakerke, Belgium). Dichotomous data were given as absolutenumbers (percent), and continuous variableswere presented asmedian
(25th-75th percentiles) if not otherwise indicated. Univariate compari-
sons between groupswere performed with the Fisher exact test for cat-
egorical variables andwith the nonparametricMann-WhitneyU test for
continuous variables (respective P valueswere not adjusted formultiple
comparisons and are therefore descriptive only).
Receiver operating characteristic (ROC) plots were constructed, and
areas under the curve (AUCs) for the prediction of death at 90 dayswere
calculated. Cutoff values with the highest prognostic accuracies were
derived from ROC curve analyses; those same cutoff values were used
to dichotomize the variables for Cox proportional hazards regression
analyses. Furthermore, we used a continuous approach, where continu-
ous variables were log transformed and risk ratios refer to a 1-SD in-
crease in the log transformed units. Univariate and multivariate Cox
proportional hazards regression analyseswere used to analyze the asso-
ciation of IL-6, galectin 3, GDF-15, sST2, and several potential con-
founders with survival. Kaplan-Meier estimates of the distribution of
times from baseline to death were computed according to cutoff values
with the highest prognostic accuracy, and log-rank-tests were per-
formed to compare the survival curves between the groups.
Finally, we assessed the prognostic value of change of biomarker
values between baseline and after 48 hours in patients with a length
of stay more than 48 hours at the ICU. Low and high marker values
were deﬁned according to the cutoff values with the highest prognostic
accuracy for eachmarker. Patients were then stratiﬁed into 4 groups ac-
cording to marker response over time, and the corresponding 90-day
all-cause mortality rates were calculated for each group.
3. Results
3.1. Primary diagnosis and mortality rates in ICU patients
The LICU study included an unselected cohort of 530 consecutive pa-
tients admitted to our medical ICU. Baseline blood samples were drawn
within 24 hours (median, 6 hours; range, 0-22 hours) after admission to
the ICU. Primary diagnosis leading to ICU admission were cardiovascular
(n = 181, 34%), respiratory (n = 69, 13%), gastrointestinal (n = 65,
12%), neurologic (n = 54, 10%), sepsis (n = 14, 2%), metabolic (n = 74,
14%), renal disease (n = 22, 4%), postoperative (n = 26, 5%), and other
medical diseases (n = 25, 5%). The median ICU length of stay was
1.7 days (25th-75th percentile, 0.9-3.4 days), andmedian hospital length
of staywas 5.4 days (25th-75th percentile, 1.6-12.5 days). All 530patients
received follow-up, and 30 (6%) died of all causeswithin theﬁrst 48hours
after admission to the ICU, 48 (9%) died of all causes in the ICU, 83 (16%)
died of all causes in the hospital, and 118 (22%) died of all causes during
the 90-day follow-up, including 42 (8%) deaths from cardiovascular
causes during the 90-day follow-up (see Supplemental Table 1).
3.2. Baseline characteristics and prognostic value of baseline markers by
ROC curve analyses
Table 1 shows baseline patient characteristics of our unselected co-
hort of 530 ICU patients according to 90-day all-cause mortality. Pa-
tients who died were older, had higher SAPS II, and showed higher
plasma concentrations of all biomarkers (Table 1).
Supplemental Fig. 1 displays baseline SAPS II, IL-6, galectin 3, GDF-
15, and sST2 according to the primary diagnosis leading to ICU admis-
sion and 90-day all-cause mortality.
Receiver operating characteristic curves demonstrating the ability of
baseline SAPS II and biomarkers to predict 90-day all-cause mortality in
530 ICU patients are depicted in Fig. 1. The highest AUC was found for
the SAPS II (AUC, 0.812; 95% conﬁdence interval [CI], 0.629-0.711) follow-
ed by IL-6 (AUC, 0.768; 95% CI, 0.730-0.803), galectin 3 (AUC, 0.749; 95%
CI, 0.709-0.785), GDF-15 (AUC, 0.746; 95%CI, 0.707-0.783), and then sST2
(AUC, 0.744; 95% CI, 0.704-0.780). Areas under the curve, cutoff values
Table 1
Baseline patient characteristics of an unselected cohort of ICU patients (n = 530) accord-
ing to 90-day all-cause mortality
Survivors Decedents Pa
n = 412 (100%) n = 118 (100%)
Male sex, n (%) 316 (77%) 96 (81%) .317
Patients age, y 62 (47-74) 74 (59-82) b .001
Patients age ≥65 y 177 (43%) 81 (69%) b .001
SAPS II 25 (18-35) 48 (34-63) b .001
SAPS II N35 98 (24%) 86 (73%) b .001
Biochemical markers
CRP, mg/dL 0.9 (0.3-3.8) 3.5 (1.5-8.8) b .001
CRP N1.1 mg/dL 186 (45%) 94 (80%) b .001
IL-6, pg/mL 19 (7-59) 81 (38-294) b .001
IL-6 N32.3 pg/mL 149 (36%) 95 (81%) b .001
PCT, ng/mL 0.05 (0.05-0.17) 0.21 (0.05-1.13) b .001
PCT N0.09 ng/mL 134 (33%) 80 (68%) b .001
Creatinine, mg/dL 0.9 (0.8-1.2) 1.3 (0.9-2.0) b .001
Creatinine N1.17 mg/dL 103 (25%) 68 (56%) b .001
hs-cTnT, ng/L 22 (6-80) 68 (30-174) b .001
hs-cTnT N23 ng/L 99 (48%) 100 (85%) b .001
BNP, ng/L 152 (46-513) 578 (225-1456) b .001
BNP N212 ng/L 167 (41%) 91 (77%) b .001
Galectin 3, ng/mL 19 (14-29) 35 (23-56) b .001
Galectin 3 N22.3 ng/mL 150 (36%) 96 (81%) b .001
GDF-15, pg/mL 2855 (1301-6335) 7843 (3753-17 297) b .001
GDF-15 N3470 pg/mL 167 (41%) 95 (81%) b .001
sST2, ng/mL 43 (28-89) 132 (60-323) b .001
sST2 N103 ng/mL 85 (21%) 72 (61%) b .001
Data are given as number (percentages) or median (25th-75th percentiles).
Dichotomous data are given as absolute numbers (percentages), and continuous variables
were presented as median (25th-75th percentiles).
Continuous data are also shown dichotomized according to the cutoff values with the
highest prognostic accuracy which was derived from ROC curve analysis.
a Univariate comparisons between the 2 groups were performed with the Fisher exact
test for dichotomous variables and with the nonparametric Mann-Whitney U test for cat-
egorical and continuous variables (respective P valueswere not adjusted formultiple com-
Table 2
Prognostic information of age, SAPS II, and biomarkers in 530 ICU patients for 90-day all-
cause mortality
Variable AUC (95% CI) Cutoff value Prognostic accuracy
Patients age 0.671 (0.629-0.711) 65 years 60%
SAPS II 0.812 (0.777-0.845) 35 75%
CRP 0.686 (0.645-0.725) 1.1 mg/dL 60%
IL-6 0.768 (0.730-0.803) 32.3 pg/mL 68%
PCT 0.686 (0.645-0.726) 0.09 ng/mL 68%
Creatinine 0.671 (0.630-0.711) 1.17 mg/dL 71%
hs-cTnT 0.687 (0.646-0.726) 23 ng/L 59%
BNP 0.713 (0.672-0.751) 212 ng/L 63%
Galectin 3 0.749 (0.709-0.785) 22.3 ng/mL 67%
GDF-15 0.746 (0.707-0.783) 3470 pg/mL 64%
sST2 0.744 (0.704-0.780) 103 ng/mL 75%
Areas under the curve and cutoff values with the highest prognostic accuracies were de-
rived from ROC curve analyses.
40 B. Dieplinger et al. / Journal of Critical Care 34 (2016) 38–45with the highest prognostic accuracies, and the respective prognostic ac-
curacies for age, the SAPS II, and the biomarkers are displayed in Table 2.
3.3. Prognostic value of baseline markers by Cox proportional hazards
regression analyses
Results of Cox proportional hazards regression analyses using a di-
chotomized approach according to the ROC curve derived cutoff values
parisons and are therefore descriptive only).Fig. 1. Receiver operating characteristic plot demonstrating the ability of baseline SAPS II
and biomarkers at baseline to predict 90-day all-cause mortality in 530 ICU patients.with the highest prognostic accuracies are reported in Table 3. In uni-
variate analysis, patients with a SAPS II greater than 35, an IL-6 greater
than 32.3 pg/mL, a galectin 3 greater than 22.3 ng/mL, a GDF-15 greater
than 3470 pg/mL, and an sST2 greater than 103 ng/mL at baseline had
an increased risk of dying during follow-up. In the multivariate model,
SAPS II greater than 35, IL-6 greater than 32.3 pg/mL, galectin 3 greater
than 22.3 ng/mL, and sST2 greater than 103 ng/mL remained indepen-
dent mortality predictors, whereas GDF-15 greater than 3740 pg/mL
did not have an independent prognostic value (Table 3).
Furthermore,we used a continuous approach for the Cox proportional
hazards regression analyseswhere age and thebiochemicalmarkerswere
normalized by log transformation and RR refer to a 1-SD increase in the
log-transformed units, and the SAPS II was entered per point increment
(Table 4). Using this continuous approach, all markers were signiﬁcant
predictors of 90-day all-cause mortality in univariate analyses. However,
in the multivariate model, only baseline SAPS II, IL-6, and sST2 remained
independent prognostic markers (Table 4).
In light of the additive value of IL-6, galectin 3, GDF-15, and sST2 to
the routinely used SAPS II score, we performed Cox proportional haz-
ards regression analysis, with patients stratiﬁed into 4 groups according
to the respective cutoff valueswith the highest prognostic accuracies. As
shown in Supplemental Fig. 2, IL-6, galectin 3, GDF-15, and sST2 at base-
line added incremental prognostic value to the SAPS II score.
We also performed Cox proportional hazards regression analyses in
subgroups according to primary diagnosis leading to ICU admission, as
outlined in Supplemental Table 2.Table 3
Results of Cox proportional hazards regression analyzing the effect of baseline variables on





RR (95% CI) P RR (95% CI) P
Patients age ≥65 y 2.54 (1.71-3.78) b .001 1.42 (0.91-2.23) .125
Male sex 0.79 (0.49-1.27) .330 0.82 (0.51-1.34) .432
SAPS II N35 6.39 (4.24-9.63) b .001 2.69 (1.70-4.26) b .001
CRP N1.1 mg/dL 4.04 (2.56-6.40) b .001 1.05 (0.60-1.85) .858
IL-6 N32.3 pg/mL 5.68 (3.59-8.99) b .001 2.41 (1.41-4.12) .001
PCT N0.09 ng/mL 3.60 (2.42-5.33) b .001 0.70 (0.40-1.22) .212
Creatinine N1.17 mg/dL 3.58 (2.46-5.22) b .001 1.06 (0.67-1.67) .813
hs-cTnT N23 ng/L 5.52 (3.25-9.37) b .001 1.60 (0.86-2.97) .135
BNP N212 ng/L 3.97 (2.57-6.12) b .001 1.51 (0.91-2.51) .109
Galectin 3 N22.3 ng/mL 6.26 (3.98-10.07) b .001 1.97 (1.10-3.52) .023
GDF-15 N3470 pg/mL 4.83 (3.05-7.64) b .001 1.07 (0.61-1.88) .826
sST2 N103 ng/mL 4.62 (3.17-6.75) b .001 2.00 (1.23-3.28) .006
RR indicates risk ratio.
a Age, SAPS II, and the biochemical markers were dichotomized according to cutoff
values with the highest prognostic accuracy whichwere derived from ROC curve analysis.
b Univariate analyses.
c Multivariate model without variable selection technique (all variables listed above
were included simultaneously into the model as independent variables).
Table 4
Results of Cox proportional hazards regression analyzing the effect of baseline variables on
90-day all-cause mortality in 530 ICU patients using a continuous approach
Variablea Univariate analysesb Multivariate modelc
RR (95% CI) P RR (95% CI) P
Patients age 2.05 (1.55-2.72) b .001 1.45 (0.99-2.10) .053
Male sex 0.79 (0.49-1.27) .330 0.79 (0.49-1.30) .355
SAPS II 1.05 (1.04-1.06) b .001 1.03 (1.02-1.05) b .001
CRP 2.12 (1.63-2.75) b .001 1.00 (0.68-1.47) .993
IL-6 2.12 (1.82-2.47) b .001 1.65 (1.29-2.11) b .001
PCT 1.55 (1.34-1.79) b .001 0.63 (0.47-0.83) .001
Creatinine 1.46 (1.27-1.67) b .001 0.95 (0.74-1.23) .706
hs-cTnT 1.55 (1.32-1.84) b .001 1.05 (0.82-1.34) .727
BNP 1.92 (1.58-2.33) b .001 1.11 (0.84-1.44) .487
Galectin 3 1.93 (1.65-2.27) b .001 1.18 (0.88-1.57) .276
GDF-15 2.06 (1.72-2.46) b .001 1.04 (0.77-1.39) .808
sST2 2.01 (1.72-2.35) b .001 1.52 (1.14-2.01) .004
a Age and the biochemical markers were normalized by log transformation. Risk ratios
refer to a 1-SD increase in the log-transformed units. Simpliﬁed Acute Physiology Score II
was entered per point increment.
b Univariate analyses.
c Multivariate model without variable selection technique (all variables listed above
were included simultaneously into the model as independent variables).
41B. Dieplinger et al. / Journal of Critical Care 34 (2016) 38–453.4. Prognostic value of baseline markers by Kaplan-Meier curve analyses
We constructed Kaplan-Meier curves for SAPS II, IL-6, galectin, GDF-
15, and sST2 at baseline, and the entire cohort was stratiﬁed according
to the respective cutoff values with the highest prognostic accuracies
(Fig. 2). Mortality was signiﬁcantly higher in patients with increased
SAPS II, IL-6, galectin 3, GDF-15, and sST2 (log-rank test, P b .001, for
each).Mortality rates at 90 days for patients with baseline SAPS II great-
er than and less than 35were 47% (n= 86) vs 9% (n= 32), for patients
with baseline IL-6 greater than and less than 32.3 pg/mLwere 39% (n=
72) vs 8% (n = 23), for patients with baseline galectin 3 greater than
and less than 22.3 ng/mLwere 39% (n=96) vs 8% (n=22), for patients
with baseline GDF-15 greater than and less than 3470 pg/mL were 36%
(n = 95) vs 9% (n = 23), and for patients with baseline sST2 greater
than and less than 103 ng/mL were 46% (n = 72) vs 12% (n = 46).
3.5. Prognostic value of a combinedmultimarker approach of baseline SAPS
II, IL-6, and sST2
Because only the SAPS II, IL-6, and sST2 were independent prognos-
tic markers in both multivariate models, we further evaluated a simple
multimarkermodel combining these 3markers.We stratiﬁed the entire
cohort according to the respective cutoff values with the highest prog-
nostic accuracies (SAPS II N35, IL-6 N32.3 pg/mL, and sST2
N103 ng/mL). Fig. 3 displays the Kaplan-Meier curves of survival ac-
cording to the presence of none, 1, 2, or 3 markers above the cutoff
value for the prediction of 90-day all-cause mortality (log-rank tests
for trend, P b .001). Of the 530 ICU patients, 215 patients had no in-
creasedmarker, 126 patients had 1, 108 had 2, and 81 patients had 3 in-
creased markers at baseline. During follow-up, lowest rates of death
were observed in patients with no increased marker, with a 5% (n =
10) death rate. In patients with 1 increased marker, death rates of 11%
(n = 14) were observed. The patients with 2 increased markers
displayed death rates of 40% (n = 43). Finally, highest death rates
were observed in patients with 3 increased markers, with a 63% (n =
51) death rate.
3.6. Prognostic value of change of markers over time
Of the 530 patients, 227 patients had a length of stay greater than
48 hours at the ICU, and of them, 225 patients had a second blood sam-
ple drawn approximately 2 days (median, 47 hours; range 38-57 hours)
after the baseline blood draw. During the 90-day follow-up, 65 (29%) of
the 225 patients died.We assessed the prognostic value of change of markers between
baseline and after 48 hours. According to the previously deﬁned cutoff
values of 35 for the SAPS II, 32.3 pg/mL for IL-6, 22.3 ng/mL for galectin
3, 3470 pg/mL for GDF-15, and 103 ng/mL for sST2, we deﬁned low and
highmarker values at baseline and after 48 hours. We stratiﬁed the 225
patients into 4 groups according to marker response over time: low to
low (stayed below cut off value), high to low (above cutoff value to
below cutoff value), low to high (below cutoff value to above cutoff
value), and high to high (stayed above cutoff value) (Fig. 4).
Patientswith SAPS II, IL-6, galectin 3, GDF-15, and sST2 below the re-
spective cutoff value at baseline and after 48 hours (ie, low to low)
showed lowmortality rates (13% for SAPS II, 7% for IL-6, 15% for galectin
3, 11% for GDF-15, and 15% for sST2), whereas patients with both values
above these cutoff value (ie, high to high) had highmortality rates (50%
for SAPS II, 41% for IL-6, 44% galectin 3, 40% for GDF-15, and 44% for
sST2). Simpliﬁed Acute Physiology Score II and IL-6 changes from high
to low or low to high showed intermediate mortality rates (27% and
23% for SAPS II, 29% and 26% for IL-6). Galectin 3 changes from high to
low showed intermediate mortality rates (30%), whereas there were
only 2 patients with a galectin 3 changes from low to high, which did
not allow a reliable calculation of mortality rates (0%) in this group.
Growth differentiation factor 15 changes from high to low displayed
rather low mortality rates (16%), and GDF-15 changes from low to
high had high mortality rates (54%). Soluble ST2 changes from high to
low also showed intermediate mortality rates (29%) but were lower
than sST2 changes from low to high (41%) (Fig. 4).
4. Discussion
We assessed the prognostic value of IL-6 (a well-established inﬂam-
matory biomarker) and galectin 3, GDF-15 and sST2 (emerging prog-
nostic biomarkers) in an unselected cohort of adult patients admitted
to a medical ICU. In this heterogeneous group of critically ill patients,
only IL-6 and sST2 at baseline remained independent biomarkers
adding additional prognostic information to the routinely used SAPS II.
Using a simple multimarker approach combing the SAPS II, IL-6, and
sST2 at baseline, we identiﬁed patients at low, intermediate, and high
risks for 90-day all-cause mortality.
In the present study, we rigorously examined a combination of in-
ﬂammatory, renal, and cardiac biomarkers besides the routinely used
severity score (SAPS II) for all-cause mortality prediction in adult, criti-
cally ill patients admitted to an ICU. In doing so,wemodeled eachmark-
er individually and collectively, using a continuous and a dichotomized
approach as well as integrating results over time.
Mediators of acute inﬂammation and infection such as CRP, IL-6, and
PCT have long been implicated in the pathophysiology of critical illness
and are routinely used at the ICU for diagnosis, prognosis, and treatment
monitoring [5,9,10]. In our unselected cohort of ICU patients, IL-6 at
baseline remained an independent prognostic marker, whereas CRP
and PCT lost their prognostic value in the multivariate models, indicat-
ing that the faster response of IL-6 on inﬂammatory stimuli might give
an advantage in risks prediction of ICU patients at admission. In this
context, several reports have indicated that IL-6 is an excellent biomark-
er for detection of early sepsis, whereas CRP and PCT are often still with-
in the reference range due to their rather slow kinetics [11–13].
Previous clinical studies have shown that increased plasma concen-
trations of established cardiacmarkers (cardiac troponins andnatriuret-
ic peptides) are associated with adverse outcomes in critically ill
patients [14–19]. In our cohort, both hs-cTnT andBNPwere strongprog-
nosticmarkers in univariate analyses but did not add independent prog-
nostic value in our multivariate models. Our ﬁndings are somewhat in
contrast to recent studies where cardiac troponins and natriuretic pep-
tides were proposed to be independent prognostic markers [18–19].
However, it has also been reported that the additional prognostic
value of cardiac troponins and natriuretic peptides is attenuated or
even gets lost after adjustment for clinical variables and/or severity
Fig. 2. Kaplan-Meier plots showing survival according to increased SAPS II (N35) (A), IL-6 (N32.3 pg/mL) (B), galectin 3 (N22.3 ng/mL) (C), GDF-15 (N3470 pg/mL) (D), and sST2
(N103 ng/mL) (E) in 530 ICU patients.
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where we extensively adjusted for biomarkers as well as the SAPS II,
that both cardiac biomarker lots their prognostic value.
The present study is the ﬁrst to assess the prognostic value of 3
emerging biomarkers, namely, galectin 3, GDF-15, and sST2 head to
head in critically ill patients. In this unselected cohort of ICU patients,
galectin 3, GDF-15, and sST2 showed similarly high AUCs for the predic-
tion of all-cause mortality. When dichotomized according to cutoff
values with the highest prognostic accuracies, patients with increased
galectin 3, GDF-15, or sST2 at baseline showed a signiﬁcantly higher
risk of death at 90 days in univariate analyses and provided incremental
prognostic information to the SAPS II. In the fully adjusted dichotomized
model, GDF-15 had no independent prognostic value. Furthermore,when using a continuous approach, both galectin 3 and GDF-15 had
no independent prognostic value. Soluble ST2 was the only emerging
biomarker that remained an independent predictor in bothmultivariate
analyses. In this context, it is important to note that an emerging bio-
marker should not only provide prognostic informationwhen used con-
tinuously but also ideally also have an optimized cutoff, which allows an
easier implementation in clinical routine.
All 3 biomarkers have been reported to be increased in various car-
diac and noncardiac diseases and are associated with disease severity
[4,22–24]. Furthermore, there is increasing evidence that these 3
emerging biomarkers provide prognostic information in patients with
various disease independently of and additive to other established car-
diacmarkers such as cardiac troponins or natriuretic peptides [4,22–24].
Fig. 3.Kaplan-Meier plots showing survival according to a combined-biomarker approach in 530 ICU patients, where the entire cohortwas stratiﬁed according to the number of increased
markers (SAPS II N35 ng/mL, IL-6 N32.3 pg/mL, and sST2 N103 ng/mL).
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3 emergingbiomarkers in critically ill patients. Critically ill patients are a
heterogeneous group, with a variety of acute and chronic disease states.
Increased plasma concentrations of galectin 3, GDF-15, and sST2 are be-
lieved to reﬂect various stress signals (inﬂammation, pathogens, ische-
mia, tissue injuries, etc) and their role on disease progression [4,25–31].
Galectin 3, GDF-15, and sST2 are not cardiac speciﬁc but rather repre-
sent general biomarkers of disease and mortality [4,25–31]. In line
with the current literature, all 3 emergingbiomarkerswere strongprog-
nostic markers in our unselected ICU cohort with a broad case-mix of
various diseases. Interestingly, in the present study, comparing these 3
emerging prognostic biomarkers head to head, sST2 outperformed
galectin 3 and GDF-15 for all-cause mortality prediction at 90 days.
Although we demonstrate that galectin 3, GDF-15, and sST2 are
emerging prognostic biomarkers in critically ill patients, it remains un-
clear of whether speciﬁc treatment to lower these biomarkers can im-
prove prognosis. There are, however, intriguing mouse data that
manipulation of galectin 3, GDF-15, or sST2 might be promising new
therapeutic targets for critical illness [32–34]. Measurement of these
emerging prognostic biomarkers could possibly also be implicated in
the monitoring of future treatment strategies of critically ill patients.
This is, however, only speculative and needs further investigations.
Because SAPS II, IL-6, and sST2 remained they only independent pre-
dictors, we further assessed a simple multimarker approach combining
the SAPS II and the 2 biomarkers IL-6 and sST2. Using this simple
multimarker model combining these 3 markers, we identiﬁed patients
at low, intermediate, and high risks for 90-day all-cause mortality. For
each additional marker increased in this combined model, we found a
rising incremental risk of death. Patients with no increased markers
displayed death rates of only 5%, whereas patients with increases in all
3 markers experienced the poorest outcome, with death rates of 63%.
Thus, a combination of the SAPS II with these 2 complementary bio-
markers might provide a valuable tool for risk stratiﬁcation of critically
ill patients. In this context, it has recently been stated that, to ﬁnd new
strategies for effective therapeutics in critically ill patients, selection of
critically ill patients for clinical trials should not only be based on clinical
variables but also include biomarkers [35].
The present study is a single-center study performed in a medical
ICU of a tertiary care hospital with predominantly male patients and
may therefore not accurately represent the general demographics of pa-
tients admitted to an ICU. Amajor limitation of the LICU study is thatwe
were not able to perform subgroup analysis for the different diseases
leading to ICU admission. Therefore, our simple multimarker approach
needs to be further validated in independent and larger cohorts of crit-
ically ill patients.In addition, we evaluated the prognostic value of SAPS II, IL-6,
galectin 3, GDF-15, and sST2 in time course. As expected, patients with
high markers at baseline and after 48 hours showed the highest risk of
death, whereas patients with low markers at both time points had the
lowest risk of death. However, when comparing the prognostic infor-
mation of serialmeasurementswith the prognostic information of base-
line values alone, the additive value can be considered rather low and
may clinically not be relevant. Reasons for these observations might
be the relatively short time interval between sample collections in our
study. Furthermore, in the present study, we have not collected data
on the time of onset of symptoms before admittance to the ICU. Finally,
we recruited an unselected cohort of patients admitted to our ICU.
Therefore, our study consists of a broad case-mix of various diseases,
and we were not able to reliably assess serial measurements for each
of the disease groups. Further studies are needed to evaluate serial bio-
marker measurements at different time points, taking into account the
time onset of symptoms, as well as being adequately powered to assess
different disease groups of critically ill patients.
5. Conclusions
In this head-to-head comparison of galectin 3, GDF-15, and sST2 in
an unselected cohort of critically ill patients, we demonstrated that
sST2 outperformed galectin 3 and GDF-15 for the prediction of 90-day
all-cause mortality. Furthermore, in this heterogeneous group of criti-
cally ill patients, only SAPS II, IL-6, and sST2 remained independent
and additive prognostic markers. Using a simplemultimarker approach,
patients with increased SAPS II, IL-6, and sST2 had the poorest outcome.
Thus, a combination of the SAPS II with the 2 complementary bio-
markers might provide a valuable tool for risk stratiﬁcation of critically
ill patients. However, the essential question,whether the results of SAPS
II, IL-6, and sST2measurement, would alter our management of critical-
ly ill patients is still pending. Interventional studies based on the deter-
mination of SAPS II, IL-6, and sST2 in critically ill patients are needed.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jcrc.2016.03.020.
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